Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results. The ...

The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 ...

Compared with chemotherapy, neoadjuvant chemoimmunotherapy led to better event-free survival and complete responses but not overall survival in patients with resectable non–small cell lung cancer ...

Please provide your email address to receive an email when new articles are posted on . PFS rates at 30 months appeared similar between patients in the radiation and observation groups. Longer ...

or on the link below. Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of patients with advanced non–small cell lung cancer without driver genetic alterations ...

Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL). Large scale ...

Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses. Patients with extensive-stage small cell lung ...

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities. Omitting ...

Cutting-edge cancer treatments like immunotherapy are offering new hope for patients, often in combination with more common approaches such as chemotherapy. But determining the best treatment ...

In a phase 2 trial of nonurothelial MIBC, half of patients receiving neoadjuvant chemoimmunotherapy showed no residual cancer at the time of surgery. In a recent phase 2 trial, neoadjuvant ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...